Reich, Gernot ; Cornely, Oliver A. 
; Sandherr, Michael ; Kubin, Thomas ; Krause, Stefan ; Einsele, Hermann ; Thiel, Eckhard ; Bellaire, Tanja ; Dörken, Bernd ; Maschmeyer, Georg
Alternative Links zum Volltext:DOIVerlag
| Dokumentenart: | Artikel |
|---|
| Titel eines Journals oder einer Zeitschrift: | British Journal of Haematology |
|---|
| Verlag: | WILEY |
|---|
| Ort der Veröffentlichung: | HOBOKEN |
|---|
| Band: | 130 |
|---|
| Nummer des Zeitschriftenheftes oder des Kapitels: | 2 |
|---|
| Seitenbereich: | S. 265-270 |
|---|
| Datum: | 2005 |
|---|
| Institutionen: | Medizin > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
|---|
| Identifikationsnummer: | | Wert | Typ |
|---|
| 10.1111/j.1365-2141.2005.05608.x | DOI |
|
|---|
| Stichwörter / Keywords: | EARLY INFECTIOUS COMPLICATIONS; FEBRILE NEUTROPENIC PATIENTS; CEFTAZIDIME PLUS AMIKACIN; COMBINATION THERAPY; MULTIPLE-MYELOMA; CANCER-PATIENTS; DOUBLE-BLIND; MEROPENEM; FEVER; LYMPHOMA; autologous stem cell transplantation; febrile neutropenia; meropenem; piperacillin; tazobactam; monotherapy |
|---|
| Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin |
|---|
| Status: | Veröffentlicht |
|---|
| Begutachtet: | Ja, diese Version wurde begutachtet |
|---|
| An der Universität Regensburg entstanden: | Ja |
|---|
| Dokumenten-ID: | 70623 |
|---|
Web of Science
Zusammenfassung
We report on 232 patients undergoing autologous haematopoietic stem cell transplantation (ASCT) entered into a multicentre, randomised trial comparing the efficacy and tolerability of meropenem (MPM) with that of piperacillin/tazobactam (P/T) as empirical antimicrobial first-line therapy for febrile neutropenia. In 27.6% of patients in the MPM group and 22.4% in the P/T group, therapy was ...
Zusammenfassung
We report on 232 patients undergoing autologous haematopoietic stem cell transplantation (ASCT) entered into a multicentre, randomised trial comparing the efficacy and tolerability of meropenem (MPM) with that of piperacillin/tazobactam (P/T) as empirical antimicrobial first-line therapy for febrile neutropenia. In 27.6% of patients in the MPM group and 22.4% in the P/T group, therapy was initially supplemented with a glycopeptide for venous catheter infection or bacteraemia because of coagulase-negative staphylococci. Complete response rate after 72 h was 63.8% in the MPM group and 49.6% in the P/T group (P = 0.034). Overall complete response rate after treatment modification was 94.0% in the MPM group and 93.1% in the P/T group. Median time to defervescence was 2 d in the MPM group and 3 d in the P/T group. The most frequently isolated pathogens were Gram-positive cocci. Treatment was well tolerated in both groups. One patient (0.4%) died from infection. Empirical first-line therapy with MPM as well as with P/T is safe and effective in febrile episodes emerging after ASCT. Higher response rates to primary treatment can be achieved with MPM.
Altmetric